Results 1 to 10 of about 272,653 (310)

Enzymatic Laccase Nanoreactors Induce Apoptosis in MOLT-4-ALL Cells and Activate Prodrugs in a Synergetic Effect. [PDF]

Blood Lymphat Cancer
Medrano-Villagómez CA, Loredo-García E, Gasperin-Bulbarela J, Vazquez-Duhalt R.   +3 more
europepmc   +1 more source

Optimising patient centred drug development to realise impact. [PDF]

Commun Med (Lond)
Calvert M, Kamudoni P, Yap C, Snyder C, Wilson R, Aiyegbusi OL.   +5 more
europepmc   +1 more source

Pharmacokinetic Drug-Drug Interaction Potential of Oral Anticancer Drugs. [PDF]

Clin Pharmacol Ther
Alhurayri F, Younis IR, Jalal SI, Logan TF, Maniar R, Bray SM, Quinney SK, Desta Z, Skaar TC, Tisdale JE, Shugg T.   +10 more
europepmc   +1 more source

Risk factors for drug-related impaired gastric emptying: a pharmacovigilance analysis of the FDA adverse event reporting system. [PDF]

Front Pharmacol
Chen JH, Chen JC, Mei YJ, Zhu XC, Luo QM, Tu YY.   +5 more
europepmc   +1 more source

A Comparison of Regional Decisions for Doses and Administrations of New Drugs: Concordance, Discordance, and Dependencies. [PDF]

Clin Pharmacol Ther
Mita S, Ono S.
europepmc   +1 more source

FDA Approval Summary: Pembrolizumab for the Treatment of HER2-Positive Gastric Cancer. [PDF]

Clin Cancer Res
Casak SJ, Zhang Y, Song C, Mishra-Kalyani PS, Tang S, Auth D, de Claro RA, Pazdur R, Lemery SJ.   +8 more
europepmc   +1 more source

FDA approvals of specialty drugs, 2000-2024. [PDF]

Health Aff Sch
Knox SE, Brennan CH, Enright DE, Neumann PJ, Chambers JD.   +4 more
europepmc   +1 more source

The Saudi FDA drug evaluation timeline in comparison with international counterparts: a retrospective observational study. [PDF]

J Pharm Policy Pract
Algabbani AM, Hafiz R, AlWon B.
europepmc   +1 more source